Breast cancer research and the European Union Clinical Trials Directive
AUTOR(ES)
Williams, Norman
FONTE
BioMed Central
RESUMO
Running clinical trials in the commercial sector has always been associated with a certain amount of bureaucracy due to the stringent requirements needed to bring a new drug onto the market. Noncommercial trials have largely been performed outside these requirements. New legislation brought about as a result of the implementation of the European Union Clinical Trials Directive will change this two-tiered approach by harmonizing regulations in all member states. Those who run noncommercial clinical trials will have to find cost-effective ways of dealing with this legislation if such work is to continue in Europe.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=468644Documentos Relacionados
- New European clinical trials directive: Is European research possible?
- Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
- Doctors disagree about directive on European clinical trials
- Implementing the European clinical trials directive: Discussions continue in the European Commission and the United Kingdom
- Introducing Breast Cancer Research's updates on clinical trials
